| Name | N-[2-(diethylamino)ethyl]-3-[4-[[4-(2-oxo-3H-benzimidazol-1-yl)piperidin-1-yl]methyl]phenyl]-2-phenylquinoxaline-6-carboxamide |
|---|---|
| Synonyms |
Merck-22-6 >=
Merck-22-6 (KRC380) Akt1/Akt2-IN-2 N-(2-(diethylamino)ethyl)-3-(4-((4-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)methyl)phenyl)-2-phenylquinoxaline-6-cboxamide N-[2-(diethylamino)ethyl]-3-(4-{[4-(2-oxo-2,3-dihydro-1H-1,3-benzodiazol-1-yl)piperidin-1-yl]methyl}phenyl)-2-phenylquinoxaline-6-cboxamide 6-Quinoxalinecboxamide, N-[2-(diethylamino)ethyl]-3-[4-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]methyl]phenyl]-2-phenyl |
| Description | Akt1/Akt2-IN-2 (compound 7) is an allosteric dual Akt1 and Akt2 inhibitor (IC50=138 nM and 212 nM, respectively). Akt1/Akt2-IN-2 increases activity of caspase-3, and inhibits viability of a number of tumor cells[1]. |
|---|---|
| Related Catalog | |
| Target |
Akt1:138 nM (IC50) Akt2:212 nM (IC50) Akt3:7.2 mM (IC50) Caspase-3 |
| In Vitro | Akt1/Akt2-IN-2 (compound 7) 对 LnCaP,HT29,MCF7,A2780 细胞有细胞毒性[1]。 Akt1/Akt2-IN-2 (2 μM, 4 μM) 分别在2 μM和4 μM时,诱导 LnCaP 细胞中 caspase-3 的活性增加 3 倍或 6.6 倍[1]。 |
| References |
| Molecular Formula | C40H43N7O2 |
|---|---|
| Molecular Weight | 653.81500 |
| Exact Mass | 653.34800 |
| PSA | 102.90000 |
| LogP | 7.44050 |